ClinicalTrials.gg
CompletedNCT01472614Updated May 27, 2013

Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes Mellitus

A Phase 3 interventional study of DLBS3233 in Type-2 Diabetes Mellitus, sponsored by Dexa Medica Group. Completed at 2 sites in Indonesia. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-05-27.

Sponsored by Dexa Medica Group · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia — 9 open to participants now, 10 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Indonesia.

Enrollment
35th of 52
54 · median 85
Started
2011
with 1 other
Phase 3
9 of 66
1 open now
Registered
14th of 66
by date
Lead sponsor
5 of 66
Dexa Medica Group

Among the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, this one is the 35th largest by enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2011, is one of 9 in phase 3, and was the 14th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

9 of the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, or all of them as a file.
02

Study summary

This is an open clinical study for 12 weeks of therapy to investigate clinical efficacy and safety of an add-on therapy with DLBS3233 in improving blood glucose control, lipid profile, and adiponectin in subjects with type-2 diabetes mellitus.

Read the detailed description

There will only be one group in this study who will receive study treatment as follows: anti-diabetic agents currently used by respective subjects for at least 3 months prior to Screening, treatment intensification (lifestyle modification), and DLBS3233 at a dose of 100 mg once daily for 12 weeks.

Clinical and laboratory examinations to evaluate the investigational drug's efficacy and safety will be performed at baseline and at interval of 6 weeks over the 12-week course of therapy.

03

Conditions studied

  • Type-2 Diabetes Mellitus

Keywords

  • Type-2 diabetes mellitus
  • Add-on therapy
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male subjects with age of 40 - 70 years; or female subjects with age of 55 - 70 years () at screening
  • Diagnosed with type-2 diabetes mellitus
  • Have been being treated with a combination of two OHA for at least 3 months prior to screening
  • A1c level of >= 7.0 %
  • level of >= 10 g/dL
  • (BMI) > 18.5 kg/m2
  • Refuse insulin therapy
  • Able to take oral medicine

Exclusion criteria

Exclusion Criteria:

  • Subjects with symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
  • Uncontrolled hypertension defined as systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg
  • History of or current chronic treatment with insulin
  • History of renal and/or liver disease
  • Impaired liver function: serum > 2.5 times and positive result of chronic or acute or C test
  • Impaired renal function: serum creatinine >= 1.5 times upper limit of normal
  • Current treatment with systemic or herbal (alternative) medicines
  • Any other disease state or uncontrolled illness, which judged by the investigator, could interfere with trial participation or trial evaluation
  • Participation in any other clinical studies within 30 days prior to screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    DLBS3233

    Drug: DLBS3233

Interventions

  • Study treatment will be DLBS3233 at a dose of 100 mg once daily (for 12 weeks) in addition to current anti-diabetic treatment used by respective study subjects and treatment intensification (lifestyle modification)

    Also known as: Inlacin

06

What researchers measure

Primary outcomes

  1. Reduction of A1c level

    Reduction of A1c level from baseline after 12 weeks of treatment

    Time frame: 12 weeks

Secondary outcomes

  1. Reduction of venous A1c level

    Reduction of venous A1c level from baseline to 6 weeks of treatment

    Time frame: 6 weeks

  2. Reduction of venous FPG

    Reduction of venous FPG from baseline to every evaluation-time point

    Time frame: 6 and 12 weeks

  3. Reduction of venous 1h-PG

    Reduction of venous 1 hour-post prandial plasma glucose from baseline to every evaluation-time point

    Time frame: 6 and 12 weeks

  4. Change in fasting insulin level

    Change in fasting insulin level from baseline to every evaluation-time point

    Time frame: 6 and 12 weeks

  5. Change in HOMA-R

    Change in HOMA-R from baseline to every evaluation-time point

    Time frame: 6 and 12 weeks

  6. Change in HOMA-B

    Change in HOMA-B from baseline to every evaluation-time point

    Time frame: 6 and 12 weeks

  7. Change in adiponectin level

    Change in adiponectin level from baseline to every evaluation-time point

    Time frame: 6 and 12 weeks

  8. Change in lipid profile

    Change in lipid profile from baseline to every evaluation-time point, including: LDL-cholesterol (direct), HDL-cholesterol, total cholesterol, and triglycerides

    Time frame: 6 and 12 weeks

  9. Change in body weight

    Change in body weight from baseline to every evaluation-time point

    Time frame: 6 and 12 weeks

  10. Hematology

    Hematology parameters (Hemoglobin level, Hematocrit, Red Blood Cell count, White Blood Cell count as well as its differentials, and platelet count) will be evaluated at baseline, at interval of 6 weeks, and at the end of study

    Time frame: 6 and 12 weeks

  11. Liver function

    Liver function parameters (serum ALT, serum AST, gamma-glutamyl transferase, alkaline phosphatase, and total bilirubin levels) will be measured at baseline, at interval of 6 weeks, and at the end of study

    Time frame: 6 and 12 weeks

  12. Renal function

    Renal function parameter, i.e. serum creatinine level will be measured at baseline, at interval of 6 weeks, and at the end of study

    Time frame: 6 and 12 weeks

  13. Adverse events

    Adverse events as well as number of subjects experienced the events will be observed and evaluated during the study period (12 weeks) and until all adverse events have been recovered or stabilized.

    Time frame: 1-12 weeks

07

Study locations

2 sites
  • Private Clinic at Jl. Prof. Dr. Moestopo 164
    Surabaya, East Java, Indonesia
  • Surabaya Diabetes and Nutrition Centre, Dr. Soetomo Hospital
    Surabaya, East Java, Indonesia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Jan 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2011
First posted
Nov 16, 2011
Start
Sep 2011
Primary completionActual
Jan 2013
CompletionActual
Apr 2013
Last update
May 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01472614
Lead sponsor
Dexa Medica Group
Responsible party
Sponsor
First posted
Nov 16, 2011
Start date
Sep 2011
Primary completion
Jan 2013
Completion
Apr 2013
Last update
May 27, 2013

Study contacts

Askandar Tjokroprawiro, Prof.Dr.dr,SpPD-KEMD,FINASIM
principal investigator · Surabaya Diabetes and Nutrition Center, Dr. Soetomo Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DLBS3233

Start the discussion